Company: BIAF
Filing Date: 2025-09-18
Form Type: 424B3
Source: 0001493152-25-014066
Chunk: 19

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-09-18
Form: 424B3
Chunk 19
---
, the holders of the August Warrants will only be entitled to receive from the Company or its successor entity, as of the date of consummation of such Fundamental Transaction, the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the August Warrants that is being offered and paid to the holders of Common Stock in connection with the Fundamental Transaction, whether that consideration is in the form of cash, stock or any combination of cash and stock, or whether the holders of our Common Stock are given the choice to receive alternative forms of consideration in connection with the Fundamental Transaction.

Except as otherwise provided in the August Warrants or by virtue of such holder’s ownership of shares of our Common Stock, the holder of an August Warrant will not have the rights or privileges of a holder of our Common Stock, including any voting rights, until the holder exercises such warrant.

<div align='center'>ANTI-DILUTION ADJUSTMENTS TO MAY 2025 WARRANTS</div>

On May 7, 2025 we consummated
a best efforts public offering of an aggregate of (i) 7,784,904 shares of Common Stock, par value $0.007 per share, (ii) pre-funded warrants
to purchase up to 2,371,346 shares of Common Stock in lieu of shares, and (iii) May 2025 Warrants to purchase up to 15,234,375 shares
of Common Stock (which number of May 2025 Warrant Shares is equal to 150% of the aggregate number of shares and pre-funded Warrants sold
in the Offering). Each share and accompanying May 2025 Warrant was sold at a combined public offering price of $0.32. Each pre-funded
warrant and accompanying May 2025 Warrant was sold at a combined public offering price of $0.313.

The May 2025 Warrants contain an anti-dilution
adjustment provision, pursuant to which, upon consummation of a Dilutive Issuance (as such term is defined in the May 2025 Warrants)
the exercise price of the May 2025 Warrants would be reduced to a minimum price of $0.10 per share and, upon a reduction in the exercise price, the number of shares of Common Stock issuable upon exercise of the May 2025 Warrants was correspondingly increased.

| 10 |

<div align='center'>USE OF PROCEED